Detailed slide-by-slide text content extracted from this presentation.
Slide 01
BIOTECH
NOLOGY
- Engineering Life
- How humanity learned to read, write, and edit the code of life — from fermentation and insulin to CRISPR, mRNA vaccines, and the imminent age of programmable biology.
- DNACRISPRmRNAGene TherapySynthetic BiologyBioinformatics
- 1 / 30
Slide 02
Using Biology to Solve Problems
- What Is Biotechnology?
- Biotechnology is the use of living organisms or their components — cells, enzymes, DNA — to create or modify products, improve animals and plants, and develop microorganisms for specific uses. Humans have practiced it for 10,000 years through fermentation and selective breeding. The modern era began with the ability to directly manipulate DNA in the 1970s.
- $1.3TGlobal biotech market size (2024)
- 97MmRNA COVID vaccine doses administered globally (peak month)
- 2025Year of first regulatory CRISPR treatments
- 2 / 30
Slide 03
From Yeast to Gene Scissors
- Historical Timeline
- 8000 BCFermentation: Sumerians brew beer; Egyptians bake leavened bread. First deliberate use of biological organisms to transform materials.
- 1928Alexander Fleming discovers penicillin from Penicillium mold. The age of antibiotic medicine begins — and the realization that microbes produce medically useful compounds.
- 1953Watson, Crick, Franklin, and Wilkins determine the double-helix structure of DNA. The molecular basis of heredity becomes legible.
- 1973Cohen and Boyer achieve first recombinant DNA experiment. They insert a frog gene into bacteria — the birth of genetic engineering.
- 1982Humulin — first recombinant DNA pharmaceutical product — approved by FDA. Human insulin produced in E. coli. Biotechnology enters medicine.
- 2003Human Genome Project completes mapping of all 3 billion base pairs in the human genome. Cost: $3 billion, 13 years. Today's sequencing: $200, 24 hours.
- 2012Doudna and Charpentier publish CRISPR-Cas9 as a programmable gene-editing tool. Nobel Prize 2020. The most powerful biological technology ever developed.
- 3 / 30
Slide 04
The Central Dogma
- Molecular Biology Fundamentals
- Francis Crick's Central Dogma of molecular biology (1958) describes the flow of biological information: DNA is transcribed into RNA, which is translated into protein. Proteins are the molecular machines that do virtually everything in the cell. Understanding this flow is the basis for all of modern biotechnology.
- DNA
- The master blueprint. 3 billion base pairs of A, T, G, C in humans. Stored in chromosomes in every cell nucleus. Remarkably stable — we can read DNA from 800,000-year-old mammoth bones.
- RNA
- The working copy. Transcribed from DNA, carries instructions to ribosomes. mRNA (messenger RNA) is the relevant form for most biotech applications. Single-stranded, less stable than DNA.
- Protein
- The functional output. Chains of amino acids folded into complex 3D structures that perform virtually all biological functions — enzymes, hormones, structural proteins, antibodies, receptors.
- 4 / 30
Slide 05
Engineering Living Factories
- Recombinant DNA
- Recombinant DNA technology uses restriction enzymes (molecular scissors that cut DNA at specific sequences) and ligases (molecular glue that joins DNA strands) to cut and paste genes from one organism into another. Bacteria or yeast then express the foreign gene, producing the desired protein at scale.
- Before recombinant insulin (1982), diabetics relied on pig and cow insulin — scarce, expensive, and immunogenic for some patients. Human insulin produced in E. coli was cheaper, purer, and unlimited in supply. The same technology now produces erythropoietin (for anemia), growth hormone, clotting factors, and hundreds of other biologics.
- Human insulin (Humulin) — first recombinant drug, 1982
- Human growth hormone — replaced cadaveric HGH, preventing prion contamination
- Erythropoietin — for anemia; notoriously abused in endurance sports
- Factor VIII — for hemophilia; replaced pooled plasma products
- Hepatitis B vaccine — first recombinant vaccine, 1986
- Monoclonal antibodies — the dominant drug class of the 21st century
- 5 / 30
Slide 06
The Blockbuster Drug Class
- Monoclonal Antibodies
- Antibodies are proteins the immune system produces to target specific molecules (antigens). Monoclonal antibodies (mAbs) are laboratory-produced antibodies that bind to a single specific target with extraordinary precision. Georges Köhler and César Milstein developed hybridoma technology in 1975 to produce them at scale — Nobel Prize 1984.
- mAbs can be designed to block cancer receptors, eliminate cancer cells, neutralize inflammatory cytokines, or carry chemotherapy directly to tumor cells. They are now the single largest pharmaceutical product category, with 7 of the 10 best-selling drugs in the world being mAbs.
- Major mAb Applications
- Oncology: Herceptin (HER2+ breast cancer), Keytruda (PD-1 immune checkpoint)
- Autoimmune: Humira (TNF-alpha), Dupixent (IL-4/IL-13)
- Cardiovascular: Repatha (PCSK9 inhibitor)
- Infectious disease: COVID-19 neutralizing antibodies
- Ophthalmology: Lucentis (VEGF, macular degeneration)
- 6 / 30
Slide 07
Reading the Book of Life
- The Human Genome Project
- Announced in 1990 and completed in 2003, the Human Genome Project was a 13-year, $3 billion international collaboration to sequence all 3.2 billion base pairs of human DNA and identify all ~20,000 genes. It was the largest coordinated scientific effort since the Manhattan Project — and yielded a paradigm shift in medicine.
- What We Learned
- Humans have ~20,000 protein-coding genes — far fewer than expected (corn has more). Only 1.5% of the genome codes for proteins; the rest was initially called "junk DNA" but is now understood to regulate gene expression.
- The Sequencing Revolution
- Moore's Law has been exceeded in genomics. Cost dropped from $3B in 2003 to under $200 in 2024. Next-generation sequencing (NGS) generates data faster than computing can analyze it — the bottleneck is now interpretation.
- Clinical Impact
- Prenatal genetic testing, cancer genome profiling, pharmacogenomics (matching drugs to patient genetics), rare disease diagnosis, pathogen sequencing (COVID-19 surveillance), ancestry testing.
- 7 / 30
Slide 08
CRISPR-Cas9: Molecular Scissors
- The Gene-Editing Revolution
- CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a bacterial immune system repurposed as a genome editor. Jennifer Doudna and Emmanuelle Charpentier showed in 2012 that a guide RNA could direct the Cas9 protein to cut DNA at any specific sequence in the genome. The system is programmable, precise, and cheap.
- Compared to earlier gene editing tools (zinc finger nucleases, TALENs), CRISPR is orders of magnitude simpler, faster, and less expensive. A PhD student can now design a CRISPR edit, order the guide RNA, and execute the experiment in weeks for a few hundred dollars.
- 2020: Nobel Prize to Doudna and Charpentier
- 2023: FDA approval of Casgevy — first CRISPR therapy for sickle cell disease
- Clinical trials: CRISPR therapies for beta-thalassemia, leukemia, blindness, HIV
- Agriculture: CRISPR-edited crops (drought resistance, disease resistance) approved in Japan, US
- Next-generation: base editing, prime editing allow single-letter DNA changes without double-strand breaks
- 8 / 30
Slide 09
The Vaccine Platform That Changed Medicine
- mRNA Technology
- Katalin Karikó and Drew Weissman spent decades on overlooked mRNA research, discovering how to modify mRNA to prevent the immune system from destroying it before it could be delivered into cells. Their Nobel Prize 2023 work made the COVID-19 vaccines possible — and opened a new paradigm for medicine.
- How mRNA Vaccines Work
- 1. Sequence the pathogen's key protein (e.g., SARS-CoV-2 spike)
- 2. Synthesize mRNA encoding that protein
- 3. Encapsulate in lipid nanoparticle for cell delivery
- 4. Body's cells read the mRNA and produce the protein
- 5. Immune system learns to recognize and attack the protein
- 6. mRNA degrades within days — does not affect DNA
- Beyond COVID
- mRNA pipeline in clinical development:
- Personalized cancer vaccines (targeting individual tumor mutations)
- Influenza vaccines — annual strain updates in weeks, not months
- HIV vaccine
- Rare disease protein replacement
- Heart disease: mRNA to regenerate cardiac muscle after infarction
- 9 / 30
Slide 10
Programming Living Systems
- Synthetic Biology
- Synthetic biology applies engineering principles to biology: standardized parts (BioBricks), abstraction hierarchies, and design-build-test cycles. The goal is to design biological systems that don't exist in nature to perform useful functions.
- The iGEM (International Genetically Engineered Machine) competition, founded at MIT in 2004, became the defining institution of synthetic biology education. Teams of undergraduates design organisms to clean pollution, produce medicines, detect disease, and solve agricultural problems.
- Artemisinin production in yeast (Jay Keasling) — antimalarial drug formerly from plant only
- Spider silk proteins produced in goat milk — stronger than steel, elastic as rubber
- E. coli engineered to consume plastic and convert it to nylon
- Yeast producing opioids — "yeast to morphine" proof-of-concept (with major biosecurity implications)
- Biosensors detecting environmental pollutants, pathogens, landmines
- Minimal genome cell (Craig Venter's JCVI-syn3.0) — 473 genes, smallest viable cell
- 10 / 30
Slide 11
Fixing the Source Code
- Gene Therapy
- Gene therapy aims to treat disease by delivering functional genes into a patient's cells to replace, silence, or supplement defective genes. The concept dates to the 1970s; the first human trial was in 1990. Progress was set back by Jesse Gelsinger's death in 1999 (immune reaction to viral vector) and by leukemia in early X-SCID trials.
- Modern gene therapy has moved past these setbacks. Adeno-associated viruses (AAVs) are now the dominant vectors — efficient, mostly non-integrating, relatively safe. Zolgensma (2019) treats spinal muscular atrophy with a single IV injection — priced at $2.1 million, the most expensive drug ever approved at the time.
- Approved Gene Therapies (Selected)
- Luxturna — RPE65 mutation blindness, $850K, 2017
- Zolgensma — spinal muscular atrophy (infants), $2.1M, 2019
- Hemgenix — hemophilia B, $3.5M, 2022
- Casgevy — sickle cell disease, CRISPR-based, 2023
- Elevidys — Duchenne muscular dystrophy (partial), 2023
- 11 / 30
Slide 12
Living Cancer Drugs
- CAR-T Cell Therapy
- CAR-T (Chimeric Antigen Receptor T-cell) therapy extracts a patient's own T-cells, genetically engineers them to recognize cancer cells, expands them in the lab, and reinfuses them. The engineered cells are living drugs — they replicate in the body and can persist for years.
- The Process
- Leukapheresis → viral transduction with CAR gene → expansion culture (billions of cells) → lymphodepletion chemotherapy → reinfusion → immune expansion in vivo. 2–4 weeks from blood draw to treatment.
- Remarkable Responses
- In B-cell leukemia (ALL), CAR-T produces complete remission in 70–90% of patients who failed all other treatments. Some patients have remained in complete remission 10+ years. These were considered terminally ill.
- Current Challenges
- Cytokine release syndrome (life-threatening inflammatory response), neurotoxicity, antigen escape (cancer evolves to lose the target antigen), manufacturing cost ($375K–$475K per treatment), access in low-income settings.
- 12 / 30
Slide 13
Slide 13
- "We are the first generation that is going to genuinely have the power to alter life's genetic code. That power carries an enormous responsibility."— Jennifer Doudna, Nobel Laureate
- $200Cost of whole genome sequencing today vs. $3B in 2003
- 20,000Known monogenic (single-gene) diseases
- 95%Rare diseases with no approved treatment
- 13 / 30
Slide 14
Feeding the World
- Agricultural Biotechnology
- Genetically modified organisms (GMOs) in agriculture have been controversial since Monsanto's Roundup-Ready soybeans in 1996 — yet the science of GM safety is arguably the most studied food science topic in history. More than 2,000 studies have found no systematic health risk from approved GMO crops.
- The humanitarian case for agricultural biotech is strong: Golden Rice (beta-carotene engineered into rice) could address vitamin A deficiency that blinds 500,000 children annually. Bt cotton has reduced pesticide use by 45% in adopting countries while increasing yields. The political controversy has delayed adoption in ways that carry human cost.
- Bt crops — Bacillus thuringiensis gene produces insecticide in plant tissue
- Herbicide tolerance — Roundup-Ready crops allow no-till farming (soil conservation)
- Golden Rice — beta-carotene fortification for vitamin A deficiency
- Disease resistance — papaya ringspot virus-resistant papaya saved Hawaiian industry
- Drought tolerance — genes from drought-resistant organisms transferred to crops
- Nitrogen fixation — research to give non-legume crops their own nitrogen-fixing symbiotes
- 14 / 30
Slide 15
When Biology Meets Computing
- Bioinformatics
- The human genome contains 3 billion base pairs; a single sequencing run generates terabytes of data. Bioinformatics is the application of computer science, statistics, and mathematics to analyze biological data — without it, the genomics revolution would produce uninterpretable floods of sequence.
- AlphaFold2 (DeepMind, 2021) used AI to predict the 3D structure of proteins from amino acid sequence. It predicted structures for virtually all known proteins (~200 million) with accuracy matching experimental methods. This has accelerated drug discovery profoundly — protein structure is fundamental to drug binding and function.
- Genome assembly — stitching short sequencing reads into complete genomes
- Variant calling — identifying mutations relative to reference genome
- RNA-seq — measuring gene expression across the whole transcriptome
- Single-cell sequencing — gene expression in individual cells, not bulk tissue averages
- Metagenomics — sequencing all organisms in an environment (gut microbiome, soil samples)
- AlphaFold — protein structure prediction, 200M+ structures freely available
- 15 / 30
Slide 16
The Microbial Universe Within
- The Microbiome
- The human body contains roughly as many microbial cells as human cells — primarily in the gut. The gut microbiome encodes more than 100× more unique genes than the human genome. It influences metabolism, immunity, mental health, drug metabolism, and disease susceptibility in ways researchers are only beginning to map.
- Health Connections
- Disrupted microbiome (dysbiosis) correlates with inflammatory bowel disease, obesity, type 2 diabetes, depression, autism spectrum conditions, Parkinson's disease, and cancer treatment response.
- Interventions
- Fecal microbiota transplant (FMT) cures recurrent C. difficile infection in >90% of cases. Microbiome therapeutics (live bacterial products) are in development for IBD, obesity, and oncology.
- Challenges
- Causality vs. correlation is difficult to establish. Microbiome composition varies enormously between individuals, populations, and time — making generalizations difficult and personalization essential.
- 16 / 30
Slide 17
From Target to Treatment
- Drug Discovery
- Traditional drug discovery: identify biological target, screen millions of compounds for activity, develop lead compound, iterate through 10–15 years of preclinical and clinical testing. Average cost: $2.6 billion per approved drug. Failure rate: 90% of candidates that enter Phase 1 trials never reach patients.
- AI-assisted drug discovery compresses early stages: AlphaFold predicts protein structure, generative AI designs candidate molecules, virtual screening replaces physical compound libraries. Insilico Medicine discovered a novel fibrosis drug candidate in 18 months and $2.6M — then took it to Phase 2 clinical trials. The timeline remains long; AI helps early stages most.
- Drug Discovery Pipeline
- Target identification — which protein/pathway causes disease?
- Hit discovery — screening for compounds that interact with target
- Lead optimization — improving potency, selectivity, ADMET properties
- Preclinical — animal models, toxicology, dosing
- Phase 1 — safety in healthy volunteers (20–100 people)
- Phase 2 — efficacy signal, dose-finding (100–300 patients)
- Phase 3 — pivotal trial (1,000–3,000+ patients)
- FDA review → approval → Phase 4 surveillance
- 17 / 30
Slide 18
The Right Drug for the Right Patient
- Precision Medicine
- Precision medicine (also called personalized medicine) uses genetic, biomarker, and clinical data to target therapies to specific patient subgroups most likely to benefit. The paradigm shift: from "this drug treats this disease" to "this drug treats this variant of this disease in patients with this genomic profile."
- Herceptin (trastuzumab) only works in HER2-positive breast cancers — about 20% of cases. Companion diagnostics (genetic tests identifying likely responders) are now standard for many targeted therapies. Pharmacogenomics predicts how patients metabolize drugs based on their CYP450 enzyme genetics.
- Gleevec (imatinib) — Ph+ chronic myelogenous leukemia; 5-year survival from 30% to 89%
- Herceptin — HER2+ breast cancer; requires HER2 companion diagnostic
- Keytruda — PD-L1+ tumors; checkpoint inhibitor works only in subset
- Ivacaftor — specific CFTR mutation in cystic fibrosis; $300K/year but transforms lives
- Tumor-infiltrating lymphocytes (TIL therapy) — personalized to each patient's cancer mutations
- 18 / 30
Slide 19
He Jiankui and the Red Line
- Biotech Ethics
- In November 2018, Chinese researcher He Jiankui announced the birth of the world's first gene-edited babies — twin girls with CCR5 gene edits intended to confer HIV resistance. The scientific community reacted with near-universal condemnation. He was convicted of illegal medical practice and sentenced to 3 years in prison.
- The case crystallized the ethical fault lines in human germline editing: edits to embryos are heritable — they affect not just the individual but all descendants. Off-target effects are unknown. Informed consent is impossible for the edited child. And the specific edit chosen (CCR5 deletion) may increase susceptibility to West Nile virus and influenza.
- Somatic gene therapy (editing one person's cells): broadly accepted
- Germline editing (editing embryos, heritable): internationally condemned except for basic research
- Therapeutic cloning: producing stem cells for research, not reproduction
- Reproductive cloning: banned in most jurisdictions
- Enhancement vs. treatment: the contested boundary — where does treating disease end and enhancing human capabilities begin?
- 19 / 30
Slide 20
Dual Use and Existential Risk
- Biodefense and Biosecurity
- The same technologies enabling medical breakthroughs can be weaponized. The 2001 anthrax letters demonstrated that biological agents remain credible weapons. The COVID-19 pandemic — whether from a lab or natural origin — demonstrated the catastrophic potential of respiratory pathogens in an interconnected world.
- Synthetic biology particularly raises biosecurity concerns: as DNA synthesis becomes cheaper and more accessible, the ability to synthesize dangerous pathogens from scratch becomes more feasible. The Fink Report (2004) introduced "dual-use research of concern" (DURC) as a regulatory category, requiring oversight of research that could enable misuse.
- Gain-of-function research: enhancing pathogen transmissibility for research; debated under moratorium
- DNA synthesis screening: major suppliers check orders against dangerous pathogen databases
- Select agent regulations: CDC/USDA oversight of dangerous biological agents
- BARDA (Biomedical Advanced Research and Development Authority): US biodefense procurement
- Global Health Security Agenda: 64 countries committed to pandemic preparedness
- 20 / 30
Slide 21
Manufacturing at Scale
- Bioreactors and Scale-Up
- Developing a drug is only half the challenge — manufacturing it at scale, consistently, safely, and affordably is the other half. Biologic drugs (proteins, mAbs, cell therapies) are manufactured in living cells in stainless steel or single-use bioreactors. The process is extremely sensitive to small changes in temperature, pH, dissolved oxygen, and feed composition.
- The COVID-19 vaccine manufacturing scale-up was unprecedented — producing billions of doses globally in under a year required massive investment in manufacturing infrastructure, technology transfer, and quality systems. The mRNA platform proved particularly scalable: same lipid nanoparticle formulation, different mRNA cargo.
- Mammalian cells (CHO cells) — dominant for mAb production
- E. coli — simple proteins, very high yield, low cost
- Yeast — complex proteins, glycosylation, insulin production
- Insect cells (baculovirus) — virus-like particles, some vaccines
- Plant bioreactors — "pharming" — proteins expressed in tobacco, potato
- Single-use bioreactors — flexible, reduced contamination risk, faster scale-up
- 21 / 30
Slide 22
From Genentech to the Modern Sector
- The Biotech Industry
- Genentech (1976) was the first company founded explicitly on recombinant DNA technology — by Robert Swanson and Herbert Boyer. Their 1980 IPO raised $35 million in under an hour, the most successful biotech IPO to that point. It established the model: academic science → startup → clinical development → FDA → commercial product.
- The modern biotech sector operates through a distinctive model: small companies (often academic spinouts) pursue novel science, funded by venture capital; they partner with or are acquired by large pharma for late-stage development and commercialization. The cluster effect is powerful: Boston/Cambridge and San Francisco Bay Area dominate globally.
- 1976Genentech founded — first biotech
- ~5,000Biotech companies globally
- 14Of top 20 drugs are biologics
- $150BAnnual NIH + industry R&D spend
- 22 / 30
Slide 23
Organs in a Dish
- Organoids and Lab-Grown Organs
- Organoids are self-organizing, three-dimensional tissue cultures derived from stem cells that miniaturize the structure and function of real organs. First developed for the intestine in 2009 (Hans Clevers), they can now be made for brain, kidney, liver, lung, pancreas, and more.
- Organoids have transformed drug discovery: instead of testing on animal models (which often fail to translate), drugs can be tested on human organoids derived from patient stem cells — capturing the actual disease biology. Patient-derived organoids allow personalized drug screening: test dozens of chemotherapy regimens on a patient's own tumor organoid before treating the patient.
- Brain organoids — grown to generate cortical layers, study neurodevelopment
- Gut organoids — most established; drug testing, rare disease modeling
- Pancreatic organoids — diabetes research, insulin-producing beta cell differentiation
- Tumor organoids — patient-specific cancer testing; predict treatment response
- Heart-on-a-chip — microfluidic devices combining organoids to simulate organ interaction
- 23 / 30
Slide 24
Targeting the Biology of Aging
- Aging and Longevity
- Aging is now understood as a biological process with identifiable molecular hallmarks — genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, mitochondrial dysfunction, cellular senescence, and more. If these are biology, they are potentially targetable.
- Senescent cells — cells that stop dividing but don't die — accumulate with age and secrete inflammatory factors (the SASP) that damage surrounding tissue. Senolytics (drugs that selectively kill senescent cells) show remarkable effects in animal models: extending healthspan and reversing multiple age-related pathologies. Human trials are underway.
- Rapamycin (mTOR inhibitor) — extends lifespan in mice; used off-label by some longevity enthusiasts
- Senolytics — Dasatinib + Quercetin clear senescent cells; Phase 2 trials in humans
- NAD+ precursors — NMN, NR raise NAD levels, supporting mitochondrial function; evidence mixed
- Epigenetic reprogramming — Yamanaka factors partially reverse cellular aging in mice
- Caloric restriction mimetics — reproducing CR benefits without CR itself
- 24 / 30
Slide 25
Food from Cells and Plants
- Synthetic Meat and Alt Protein
- Cultivated meat (lab-grown meat) grows animal muscle cells in bioreactors without slaughter. The first cultivated beef burger was produced by Mark Post in 2013 at a cost of $330,000. By 2024, costs have fallen to roughly $100/kg and declining. Singapore and the US have approved cultivated chicken for sale.
- Fermentation-based proteins (mycoprotein, precision fermentation) use microorganisms to produce animal-equivalent proteins. Impossible Foods uses soy leghemoglobin produced by yeast to create heme, giving plant-based burgers their meat-like taste. The alternative protein sector is converging on multiple technological approaches simultaneously.
- Cultivated meat: cells from biopsy → growth medium → scaffold → food
- Plant-based meat: soy/pea protein textured to mimic meat fiber
- Precision fermentation: yeast/bacteria produce specific proteins (whey, egg white, heme)
- Insect protein: crickets produce protein at 12× efficiency of beef per unit of feed
- Single-cell protein: algae and yeast as direct food sources
- 25 / 30
Slide 26
The Price of Miracles
- Access and Equity
- Gene therapies that cure previously fatal diseases are priced at $1–4 million per treatment. Monoclonal antibodies average $30,000–$250,000 per year. These are transformative medicines available to wealthy-country patients with excellent insurance — and largely inaccessible to most of the world's population.
- The access paradox: the same biotechnology toolkit that produced COVID vaccines for billions also produced treatments priced for thousands. The fundamental tension between R&D cost recovery through pricing and global equitable access is the defining ethical challenge of 21st-century medicine.
- Sovaldi (Hepatitis C cure): $1,000/pill; generic version $50 total in India
- Zolgensma: $2.1M for one-time treatment; negotiated lower in some countries
- COVID mRNA vaccines: $2–$20 per dose after industrial scale-up and public subsidy
- TRIPS waiver: WTO intellectual property flexibility for pandemic medicines
- Medicines Patent Pool: voluntary licensing to enable generic production in LMICs
- 26 / 30
Slide 27
The FDA and Global Regulatory Landscape
- Regulation
- The US FDA's Center for Biologics Evaluation and Research (CBER) regulates biological products — vaccines, blood products, gene therapies, cellular therapies. CDER handles small-molecule drugs and biosimilars. Approval of a new biologic drug typically requires 10–15 years from IND application through BLA approval.
- Accelerated pathways have shortened timelines for urgent needs: Breakthrough Therapy designation, Fast Track, Accelerated Approval (surrogate endpoints), Priority Review. COVID vaccines received Emergency Use Authorization in 9–11 months — unprecedented but underpinned by accelerated (not shortened) clinical trials running simultaneously rather than sequentially.
- FDA (US) — most stringent; gold standard for global market access
- EMA (EU) — harmonized across 27 member states; mutual recognition with some partners
- PMDA (Japan) — fast acceptance of FDA/EMA data reducing duplicate trials
- NMPA (China) — rapid growth, reform toward ICH harmonization
- ICH (International Council for Harmonisation) — harmonizes technical requirements globally
- 27 / 30
Slide 28
What's Coming
- The Next Decade
- AI-Designed Drugs
- Generative AI models (AlphaFold, RFDiffusion, ESMFold) design novel proteins from scratch. First AI-designed drug candidates are in clinical trials. The bottleneck shifts from design to validation.
- In Vivo Editing
- Delivering CRISPR or base editors directly into patients (not just cells taken outside the body). Intellia's NTLA-2001 showed in vivo CRISPR editing in liver in humans — first demonstration. More targets coming.
- Programmable Immunity
- Engineering the immune system to recognize and eliminate cancer, infection, or autoimmune targets with surgical precision. Off-the-shelf CAR-T, bispecific antibodies, and NK cell therapies are reducing cost and increasing access.
- Xenotransplantation
- CRISPR-edited pig organs (with human immune compatibility genes added, pig rejection genes removed) for transplant. First pig kidney transplant to a living human in 2024. Could solve the organ shortage crisis.
- Spatial Genomics
- Sequencing gene expression within intact tissue sections — where in a tumor is each cell type? How do they interact spatially? Context that bulk or single-cell sequencing loses.
- Brain-Computer Interface
- Neuralink, Synchron, and others develop implantable devices allowing paralyzed patients to control computers with thought. Biotech and neuroscience converging on human-machine interface.
- 28 / 30
Slide 29
Key Institutions and Resources
- Essential Knowledge
- NIH National Human Genome Research Institute — genome.gov
- Broad Institute — CRISPR, genomics, psychiatric genetics
- Wellcome Sanger Institute — UK genomics, disease gene discovery
- EMBL (European Molecular Biology Laboratory) — EU life science hub
- iGEM Foundation — synthetic biology education and competition
- Johns Hopkins Center for Health Security — biosecurity research
- ClinicalTrials.gov — all registered US clinical trials
- PubMed — NIH's biomedical literature database
- bioRxiv — preprint server for biology research
- STAT News — specialist biotech journalism
- Nature Biotechnology — premier research journal
- The Code Breaker (Isaacson) — definitive CRISPR narrative
- 29 / 30
Slide 30
We Can Now Read,
Write, and Edit
the Language of Life
- The Era of Programmable Biology
- The 21st century will be defined by biotechnology the way the 20th was defined by physics. The ability to precisely modify living systems carries extraordinary promise for human health, food security, and environmental challenges — and demands commensurate wisdom in deployment.
- CRISPRmRNAGene TherapyPrecision MedicineSynthetic Biology
- 30 / 30
